Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PortugalBack to Portugal

Clinical trials in Braga – page 24

684 clinical trials in Braga, Portugal across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Braga at a glance
684
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

684 trials in Braga

Open in trial search

Acute myeloid leukaemia

Not yet recruiting

Study on the Safety of Ivosidenib and Azacitidine for Adults with Newly Diagnosed IDH1m Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Servier Affaires Medicales

Colitis ulcerative

Not recruiting

Evaluation of Long-Term Efficacy and Safety of Obefazimod as Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Guselkumab and Ustekinumab for Patients with Moderate to Severe Crohn's Disease

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Dementia Alzheimer's type

Not recruiting

Oral Semaglutide in People With Mild Cognitive Impairment or Mild Dementia of the Alzheimer’s Type

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Systemic lupus erythematosus

Not recruiting

Phase 3 study of ianalumab plus standard drug combination in adults and adolescents with systemic lupus erythematosus

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Arteriosclerosis

Not recruiting

A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Olpasiran
  • Sponsor:Amgen Inc.

Sjogren's syndrome

Not recruiting

Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Sjogren's syndrome

Not recruiting

Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Sjogren's syndrome

Not recruiting

A study to evaluate the safety of dazodalibep in patients with Sjögren's Syndrome over a long period of time

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Amgen Inc.

Chronic kidney disease+1

Not recruiting

A Study Testing How Well BAY 3401016 Works and How Safe It Is in Adults Aged 18 to 45 Years with Alport Syndrome

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years
  • Substances:BAY 3401016
  • Sponsor:Bayer AG

Squamous cell carcinoma of head and neck

Not recruiting

Testing Drug Combinations with GSK4381562A, GSK6097608, GSK4428859 and Dostarlimab in Patients with PD-L1 Positive Head and Neck Cancer That Has Spread or Returned

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Cardiac failure

Not recruiting

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Other cities in Portugal

The busiest research cities in the country

All 47 cities in Portugal

Clinical research in Braga

What the registry says about research in the country

01 Neurological Conditions

Innovative trials exploring treatments for multiple sclerosis, including chronic neuropathic pain management and new therapeutic approaches. Research also encompasses frontotemporal dementia and various types of migraines.

  • Multiple Sclerosis Treatment
  • Neuropathic Pain Management
  • Menstrual Migraine Prevention

Studies focus on both symptom management and disease modification approaches.

02 Dermatological Studies

Comprehensive research into various skin conditions, including plaque psoriasis, atopic dermatitis, and hidradenitis suppurativa. Clinical trials are evaluating new biological treatments and long-term management strategies.

  • Psoriasis Management
  • Eczema Treatment
  • Inflammatory Skin Conditions

Focus on developing targeted therapies for chronic skin conditions.

03 Immunological Disorders

Investigation of novel treatments for autoimmune conditions, including studies on lupus nephritis and immune thrombocytopenia. Research aims to develop more effective therapeutic approaches.

  • Autoimmune Disease Management
  • Immunotherapy Development
  • Blood Disorder Treatment

Emphasis on innovative immunological interventions and targeted therapies.

Back to PortugalAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.